Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16072777 | 1.00 | RAB9A (0.57) | RAB9AKDM4ENPC1SMN1; SMN2CHRM2 | |
| SCHEMBL16155136 | 1.00 | RAB9A (0.57) | RAB9AKDM4ENPC1SMN1; SMN2CHRM2 | |
| SCHEMBL11093278 | 0.86 | RAB9A (0.43) | RAB9AKDM4ENPC1SMN1; SMN2CHRM2 | |
| SCHEMBL10729344 | 0.83 | RAB9A (0.41) | RAB9AKDM4ENPC1SMN1; SMN2CHRM2 | |
| SCHEMBL13587663 | 0.81 | CHRNA7 (0.40) | RAB9AKDM4ENPC1SMN1; SMN2CHRNA7 | |
| SCHEMBL16077024 | 0.80 | RAB9A (0.41) | RAB9AKDM4ENPC1SMN1; SMN2CHRM2 | |
| SCHEMBL16155138 | 0.80 | RAB9A (0.41) | RAB9AKDM4ENPC1SMN1; SMN2CHRM2 | |
| SCHEMBL16072774 | 0.80 | RAB9A (0.41) | RAB9AKDM4ENPC1SMN1; SMN2CHRM2 | |
| SCHEMBL7160184 | 0.79 | RAB9A (0.87) | RAB9AKDM4ENPC1SMN1; SMN2CHRM2 | |
| SCHEMBL15106938 | 0.79 | RAB9A (0.87) | RAB9AKDM4ENPC1SMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781544-B1 | PROCESS FOR THE PREPARATION OF ILOPROST | EUROAPI HUNGARY LLC (HU) | 2023-11-08 | — | — | EP | disclosed |
| US-11535580-B2 | Process for the preparation of iloprost | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2022-12-27 | — | — | US | disclosed |
| US-20210147329-A1 | PROCESS FOR THE PREPARATION OF ILOPROST | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2021-05-20 | — | — | US | disclosed |
| WO-2019202345-A2 | PROCESS FOR THE PREPARATION OF ILOPROST | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2019-10-24 | — | — | WO | disclosed |
| US-9345678-B2 | Prostanoid receptor agonist compounds and methods of use for same | ALLERGAN, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140275266-A1 | PROSTANOID RECEPTOR AGONIST COMPOUNDS AND METHODS OF USE FOR SAME | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-4692464-A | Novel prostacyclin derivatives and a process for the preparation thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-09-08 | — | — | US | disclosed |
| EP-0041661-B1 | PREPARATION OF INTERMEDIATES OF CARBAPROSTACYCLINES | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-07-18 | — | — | EP | disclosed |
| US-4359581-A | Process for the production of caracyclin intermediates | SCHERING AG (DE) | 1982-11-16 | — | — | US | disclosed |
| EP-0041661-A2 | Preparation of intermediates of carbaprostacyclines | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-12-16 | — | — | EP | disclosed |
| EP-0011591-A1 | Prostane derivatives, their production and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147329-A1 | PROCESS FOR THE PREPARATION OF ILOPROST | PTGIS, PTGER1, PTGIR | RAB9A 2847/4885KDM4E 4668/4885NPC1 2183/4885 |
| US-20140275266-A1 | PROSTANOID RECEPTOR AGONIST COMPOUNDS AND METHODS OF USE FOR SAME | PTGIR, PTGER1, PTGDR | RAB9A 3876/4885KDM4E 2413/4885NPC1 3244/4885 |
| US-11535580-B2 | Process for the preparation of iloprost | PTGIS, PTGER1, PTGIR | RAB9A 2847/4885KDM4E 4668/4885NPC1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.